Docket No.: 9/200US  Serial No.: 10/074,895 Filed: February 12, 2002 For : Process for Synthesis of Heteroaryl-substituted Urea Compounds Useful as Antiinflammatory Agents  Commissioner for Patents Washington, D.C. 20231  TECH CENTER 1600/2900  July 24, 2002  SUPPLEMENTAL TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT  Sir:  Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §\$1.56 and  1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.  1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  A certification as specified in 37 C.F.R. §1.97(e); or  The fee set forth in 37 C.F.R. §1.17(p).	OIP	1 10 2002 E IN T	HE UNITED STATES	S PATENT AND TR	ADEMARK OFFICE	1625
TECH CENTER 1600/2900  July 24, 2002  SUPPLEMENTAL TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT  Sir:  Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and   1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.  1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  A certification as specified in 37 C.F.R. §1.97(e); or  The fee set forth in 37 C.F.R. §1.17(p).	NEW MEN	Assertion of Serial No. Filed	: Tan, Z. et al : 10/074,895 : February 12, 2002 : Process for Synthes	Docket I ) Art Unit ) Examine is of Heteroaryl-substi	No.: 9/200US : 1625 er: tuted Urea Compounds.	Useful VED
Sir:  Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and  1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.  1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  A certification as specified in 37 C.F.R. §1.97(e); or  The fee set forth in 37 C.F.R. §1.17(p).						
Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and  \[ \sum_{1.97(b)} \]  This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.  \[ \sum_{1.97(c)} \]  This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  \[ \sum_{1.97(c)} \]  A certification as specified in 37 C.F.R. §1.97(e); or  \[ \sum_{1.97(c)} \]  The fee set forth in 37 C.F.R. §1.17(p).		July 24, 2002	SUPPLEMENTAI INFORMATIO	. TRANSMITTAL L N DISCLOSURE ST.	ETTER FOR ATEMENT	COPY OF PAPERS ORIGINALLY FILED
national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.  1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  A certification as specified in 37 C.F.R. §1.97(e); or  The fee set forth in 37 C.F.R. §1.17(p).		Transmitted her Statement unde	r 37 C.F.R. §§1.56 and			
C.F.R. §1.97(b), but before the mailing date of either a final action under §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first. This Statement is being accompanied by:  A certification as specified in 37 C.F.R. §1.97(e); or  The fee set forth in 37 C.F.R. §1.17(p).		national application 37 C.F.R. §1	ation; within three mon .491 in an international	ths of the date of entry application; or before	of the national stage as	set forth
The fee set forth in 37 C.F.R. §1.17(p).		C.F.R. §1.97(b) of allowance up	), but before the mailing nder 37 C.F.R. §1.311,	date of either a final	action under §1.113 or a	a notice
	: · ::	<del></del> .			'(e); or	
	."		•		authorized to charge pa	ayment

of the \$240.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No.

02-2955.

1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set fort in 37 C.F.R. §1.17(i).
The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.
Triplicate copies of this form are enclosed.
Pagagathilly submitted

Respectfully submitted,

Anthony P. Bottino Attorney for Applicant(s) Reg. No. 41,629

Breth P. Botto

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope Addressed to:

Commissioner for Patents Washington, D.C. 20231

On July 24, 2002

By Anthony P. Bottino Reg. No. 41,629

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368

Ridgefield, CT. 06877 Tel.: (203) 791-6764

65	- 40%
u )	3 0 2002
DOWN	TA TRADELLE

Sheet 1

Substitute for form 1449B/PTO

**NON-PATENT DOCUMENTS** 

SUBMITTED BY APPLICANT

of

## COPY OF PAPERS

ORIGINALLY FILED RECEIVED Complete If Known 10/074,895 Application Number AUG 0 6 2002 Filing Date February 12, 2002 First Named Inventor Tan, Z. et al TECH CENTER 600/2900 Group Art Unit 1625 Examiner Name Attorney Docket Number 9/.200US

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, jounal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Τ.
BIL	AO1	International Search Report - 05/07/2002	
<b>1</b>	AO2		
	AO3		
	A04		
	A05		
	AO6		
	A07		
	AO8		
	AO9		
	AO10		10
	AO11		

	_		
Examiner /		Date Considered	6 124/ 04

IN '	THE UNITED STATES PATEN	T AND TRADE	MARK OFFICE 🔎 🛱 💂
Application of Serial No. Filed For	f: Tan, Z. et al : To be assigned : February 12, 2002 : Process for Synthesis of Heter as Antiinflammatory Agents	Docket No.: ) Art Unit: ) Examiner: roaryl-substituted	9/200US To be assigned To be assigned Urea Compounds Useful
Commissioner Washington, I			
February 12, 2	2002		
TRANSM	ITTAL LETTER FOR INFORM	IATION DISCL	OSURE STATEMENT
Sir:			
	erewith concerning the subject app ler 37 C.F.R. §§1.56 and	lication is an Info	rmation Disclosure
in 37 C.F.R. §	). This Statement is being file cation; within three months of the cation in an international application merits, whichever event occurs las	date of entry of then; or before the n	
	b), but before the mailing date of earth ander 37 C.F.R. §1.311, whichever	ither a final actior	under §1.113 or a notice
	A certification as specified in 37 (	C.F.R. §1.97(e); o	r
	The fee set forth in 37 C.F.R. §1.1	17(p).	
	The Assistant Commission of the \$240.00 fee set forth in 37 002-2955.		

1.97(d). This Statement is being filed after the mailing of either a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311, whichever occurs first, but before payment of the issue fee. This Statement is being accompanied by a certification as specified in 37 C.F.R. §1.97(e), a petition requesting consideration of this Statement, and the petition fee set fort in 37 C.F.R. §1.17(i).
The Assistant Commissioner is hereby authorized to charge payment of the \$130.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.
The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.
Triplicate copies of this form are enclosed.

Respectfully submitted,

But Alle

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

Anthony P. Bottino Attorney for Applicant(s)

Reg. No. 41,629

EXPRESS MAIL LABEL NO. EL904730340US

Deposited: February 12, 2002

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road P.O. Box 368 Ridgefield, CT. 06877 Tel.: (203) 791-6764

BY: ANTHONY P. BOTTINO

Reg. No. 41,629

PTC/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE				Compl t if Known				
				Application Number	To be assigned	0	3	
				Filing Date	February 12, 2002	6.0	3	
STATEMENT BY APPLICANT			PLICANT	First Named Inventor	Tan, Z. et al	6	31	
				Art Unit	To be assigned	S	Ξ	
(us	e as many s	sheets as ne	cessary)	Examiner Name	To be assigned	25		
Sheet	1	of	2	Attorney Docket Number	9/200US	0/0	3	
						0	7	

			U.S. PAT	ENT DOCUMENTS	Ť
Examiner initials		Document Number Number - Kind Code <sup>2</sup> (if known	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
HUIC		us- 6.319,921B1	11/20/2001	Cirillo, P.F. et al	
3un		us- 6,080,763	06/27/2000	Regan, J.R. et al	
		US-			
	ļ	US-			
		US-			
		US-			
_		US-			
·	<b> </b>	US-			
		US-			
	l	US-			L

		FORI	EIGN PATENT D	OCUMENTS		
	Cite No. <sup>1</sup>	Foreign Patent Document  Country Code 3 - Number 4 - Kind Code 3 (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
BUR		WO 00/55139 A2	09/21/2000	Boehringer Ingelheim		
7004		WO 00/55139 A3	09/21/2000	Boerhinger Ingelheim		
		WO 01/32627	10/27/2000	Boehringer Ingelheim		
		WO 01/90072	05/15/2001	Boehringer Ingelheim		
BULL		WO 01/04115	06/27/2000	Boehringer Ingelheim		_
		-				_
						<b>-</b>
					<del></del>	

Examiner	1/ //	Date	1/22/04
Signature		Considered	1_0/27/07

Engish language Transaction is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademerk Office. Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Attorney Docket Number 9/200US

Compl t if Known Substitute for form 1449B/PTO To be assigned Application Number INFORMATION DISCLOSURE February 12, 2002 Filing Date Tan, Z. et al First Named Inventor STATEMENT BY APPLICANT Group Art Unit To be assigned To be assigned (use as many sheets as necessary) Examiner Name

of

2

Sheet

Examiner

Signature

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Inilials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue oumber(s), publisher, city and/or country where published.	Т2
TUK		New Aryl/Heteroaryl C-N Bond Cross-coupling Reactions via Arylboronic Acid/Cupric Acetate Arylation PATRICK Y.S. LAM, et al; Tetrahedron Letters 39,(1998) 2941-2944	
BUIL		Application No.09/902,085 filed 07/11/2001, KAPADIA, S. et al; A NOVEL SYNTHESIS FOR HETEROARYLAMINE COMPOUNDS	
			_
			_
			_
	L		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date

Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Office, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.